JPRN-jRCT2080220270UnknownPhase 2
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
Abbott Japan Co., Ltd.0 sitesStarted: July 7, 2006Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •- Subject was age 20 or older and in good health (Investigator discretion) with a recent stable medical history.
- •- Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
- •Exclusion criteria:
- •- Subject had previously received anti-TNF therapy.
- •- Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVA, UVB or PUVA phototherapy
- •- Subject is taking or requires oral or injectible corticosteriods
- •- Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
- •- Female subject who is pregnant or breast-feeding or considering becoming pregnant
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 2
A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT00647491Abbott352
Completed
Phase 3
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis SuppurativaHidradenitis SuppurativaNCT02904902AbbVie15
Completed
Phase 3
A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT00853099AbbVie (prior sponsor, Abbott)274
Unknown
Phase 2
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsMelanomaJPRN-jRCT2080222335Bristol-Myers K.K.18
Completed
Phase 3
A Study of Adalimumab in Japanese Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT00667355Abbott41